ARCHIVES

NCI Advisors Approve Recompetition Of $132 Million Proteomic Technologies Network

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

NCI, Litton Open Talks On Frederick Contract

February 6, 1976

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

July 4, 1997

Drug Development Gets Extra $500,000

November 18, 1977

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

Group trials need prioritization, review, NCI official says.

July 25, 2003

President’s Cancer Panel annual report finds barriers in translational research stall progress.

July 8, 2005